The D173G mutation in ADAMTS-13 causes a severe form of congenital thrombotic thrombocytopenic purpura

Summary

Congenital thrombotic thrombocytopenic purpura (TTP) is a rare form of thrombotic microangiopathy, inherited with autosomal recessive mode as a dysfunction or severe deficiency of ADAMTS-13 (A Disinte-grin And Metalloprotease with ThromboSpondin 1 repeats Nr. 13), caused by mutations in the ADAMTS-13 gene. About 100 mutations of the ADAMTS-13 gene were identified so far, although only a few char-acterised by in vitro expression studies. A new Asp to Gly homozygous mutation at position 173 of ADAMTS-13 sequence was identified in a family of Romanian origin, with some members affected by clinical signs of TTP. In two male sons, this mutation caused a severe (< 3 %) deficiency of ADAMTS-13 activity and antigen level, associated with periodic thrombocytopenia, haemolytic anaemia and mild mental confusion. Both parents, who are cousins, showed the same mutation in heterozygous form. Expression studies of the mutant ADAMTS-13, performed in HEK293 cells, showed a severe decrease of the enzyme’s activity and secretion, although the protease was detected inside the cells. Molecular dynamics found that in the D173G mutant the interface area between the metalloprotease domain and the disintegrin-like domain significantly decreases during the simulations, while the proline-rich 20 residues linker region (LR, 285–304) between them undergoes extensive conformational changes. Inter-domain contacts are also significantly less conserved in the mutant compared to the wild-type. Both a decrease of the inter-domain contacts along with a substantial conformational rearrangement of LR interfere with the proper maturation and folding of the mutant ADAMTS-13, thus impairing its secretion.

Supplementary Material to this article is available online at www.thrombosis-online.com.

Keywords

Congenital thrombotic thrombocytopenic purpura - ADAMTS-13 - von Willebrand factor

^# Equal contribution.

^§ Senior coauthor.

• References

• 1 Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347: 589-600.
• 2 Vesely SK, George JN, Lammle B. et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 102: 60-68.
• 3 Levy GG, Nichols WC, Lian EC. et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-494.
• 4 Zheng X, Chung D, Takayama TK. et al. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276: 41059-41063.
• 5 Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87: 4235-4244.
• 6 Chung DW, Fujikawa K. Processing of von Willebrand factor by ADAMTS-13. Biochemistry 2002; 41: 11065-11070.
• 7 Bao J, Xiao J, Mao Y. et al. Carboxyl terminus of ADAMTS13 directly inhibits platelet aggregation and ultra large von Willebrand factor string formation under flow in a free-thiol-dependent manner. Arterioscler Thromb Vasc Biol 2014; 34: 397-407.
• 8 Peyvandi F, Lavoretano S, Palla R. et al. Mechanisms of the interaction between two ADAMTS13 gene mutations leading to severe deficiency of enzymatic activity. Hum Mutat 2006; 27: 330-336.
• 9 Peyvandi F, Lavoretano S, Palla R. et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 2008; 93: 232-239.
• 10 Assink K, Schiphorst R, Allford S. et al. Mutation analysis and clinical implications of von Willebrand factor-cleaving protease deficiency. Kidney Int 2003; 63: 1995-1999.
• 11 Bestetti G, Stellari A, Lattuada A. et al. ADAMTS 13 genotype and vWF pro-tease activity in an Italian family with TTP. Thromb Haemost 2003; 90: 955-956.
• 12 Kokame K, Miyata T. Genetic defects leading to hereditary thrombotic thrombocytopenic purpura. Semin Hematol 2004; 41: 34-40.
• 13 Licht C, Stapenhorst L, Simon T. et al. Two novel ADAMTS13 gene mutations in thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome (TTP/ HUS). Kidney Int 2004; 66: 955-958.
• 14 Studt JD, Kremer Hovinga JA, Antoine G. et al. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood 2005; 105: 542-544.
• 15 Uchida T, Wada H, Mizutani M. et al. Identification of novel mutations in ADAMTS13 in an adult patient with congenital thrombotic thrombocytopenic purpura. Blood 2004; 104: 2081-2083.
• 16 Veyradier A, Lavergne JM, Ribba AS. et al. Ten candidate ADAMTS13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome). J Thromb Haemost 2004; 02: 424-429.
• 17 Lancellotti S, Basso M, De Cristofaro R. Proteolytic Processing of Von Wille-brand Factor by Adamts13 and Leukocyte Proteases. Mediterr J Hematol Infect Dis 2013; 05: e2013058.
• 18 Plaimauer B, Fuhrmann J, Mohr G. et al. Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation. Blood 2006; 107: 118-125.
• 19 Lotta LA, Garagiola I, Palla R. et al. ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat 2010; 31: 11-19.
• 20 Camilleri RS, Scully M, Thomas M. et al. A phenotype-genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom. J Thromb Haemost 2012; 10: 1792-1801.
• 21 Donadelli R, Banterla F, Galbusera M. et al. In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. Thromb Haemost 2006; 96: 454-464.
• 22 De Cristofaro R, Peyvandi F, Baronciani L. et al. Molecular mapping of the chloride-binding site in von Willebrand factor (VWF): energetics and conformational effects on the VWF/ADAMTS-13 interaction. J Biol Chem 2006; 281: 30400-30411.
• 23 Gardner MD, Chion CK, de Groot R. et al. A functional calcium-binding site in the metalloprotease domain of ADAMTS13. Blood 2009; 113: 1149-1157.
• 24 Oggianu L, Lancellotti S, Pitocco D. et al. The oxidative modification of von Willebrand factor is associated with thrombotic angiopathies in diabetes mellitus. PLoS One 2013; 08: e55396.
• 25 De Cristofaro R, Peyvandi F, Palla R. et al. Role of chloride ions in modulation of the interaction between von Willebrand factor and ADAMTS-13. J Biol Chem 2005; 280: 23295-2302.
• 26 Akiyama M, Takeda S, Kokame K. et al. Crystal structures of the noncatalytic domains of ADAMTS13 reveal multiple discontinuous exosites for von Wille-brand factor. Proc Natl Acad Sci USA 2009; 106: 19274-19279.
• 27 Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993; 234: 779-815.
• 28 Gerhardt S, Hassall G, Hawtin P. et al. Crystal structures of human ADAMTS-1 reveal a conserved catalytic domain and a disintegrin-like domain with a fold homologous to cysteine-rich domains. J Mol Biol 2007; 373: 891-902.
• 29 Mosyak L, Georgiadis K, Shane T. et al. Crystal structures of the two major aggrecan degrading enzymes, ADAMTS4 and ADAMTS5. Protein Sci 2008; 17: 16-21.
• 30 Shieh HS, Mathis KJ, Williams JM. et al. High resolution crystal structure of the catalytic domain of ADAMTS-5 (aggrecanase-2). J Biol Chem 2008; 283: 1501-1507.
• 31 Wallner B, Elofsson A. Can correct protein models be identified?. Protein Sci 2003; 12: 1073-1086.
• 32 Benkert P, Kunzli M, Schwede T. QMEAN server for protein model quality estimation. Nucleic Acids Res 2009; 37 Web Server issue W510-514.
• 33 DeLano Scientific L. http://wwwpymolorg 2002.
• 34 Hess B, Bekker H, Berendsen HJC. et al. LINCS: A linear constraint solver for molecular simulations. J Comput Chem 1997; 18: 1463.
• 35 Lindorff-Larsen K, Piana S, Palmo K. et al. Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins 2010; 78: 1950-1958.
• 36 Jorgensen WL, Duffy EM, Tiradorives J. Comparison of simple potential functions for simulating liquid water. J Chem Phys 1983; 83: 926.
• 37 Darden T, York D, Pedersen L. Particle Mesh Ewald – an N. Log(N) Method for Ewald Sums in Large Systems. J Chem Phys 1993; 98: 10089.
• 38 Bussi G, Donadio D, Parrinello M. Canonical sampling through velocity rescaling. J Chem Phys 2007; 126: 014101.
• 39 Parrinello M, Rahman A. Polymorphic Transitions in Single-Crystals – a New Molecular-Dynamics Method. J Appl Phys 1981; 52: 7182.
• 40 Abdel-Azeim S, Chermak E, Vangone A. et al. MDcons: Intermolecular contact maps as a tool to analyze the interface of protein complexes from molecular dynamics trajectories. BMC Bioinformatics 2014; 15 (Suppl. 05) S1.
• 41 Furlan M, Robles R, Lammle B. Partial purification and characterisation of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87: 4223-4234.
• 42 Crawley JT, de Groot R, Xiang Y. et al. Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor. Blood 2011; 118: 3212-3221.
• 43 de Groot R, Bardhan A, Ramroop N. et al. Essential role of the disintegrin-like domain in ADAMTS13 function. Blood 2009; 113: 5609-5616.
• 44 Liu T, Qian WJ, Gritsenko MA. et al. Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry. J Proteome Res 2005; 04: 2070-2080.
• 45 Zhou W, Tsai HM. N-Glycans of ADAMTS13 modulate its secretion and von Willebrand factor cleaving activity. Blood 2009; 113: 929-935.
• 46 Ricketts LM, Dlugosz M, Luther KB. et al. O-fucosylation is required for ADAMTS13 secretion. J Biol Chem 2007; 282: 17014-17023.
• 47 Hebert DN, Molinari M. In and out of the ER: protein folding, quality control, degradation, and related human diseases. Physiol Rev 2007; 87: 1377-1408.
• 48 Stevens FJ, Argon Y. Protein folding in the ER. Semin Cell Dev Biol 1999; 10: 443-454.
• 49 Majerus EM, Zheng X, Tuley EA. et al. Cleavage of the ADAMTS13 propeptide is not required for protease activity. J Biol Chem 2003; 278: 46643-46648.